Literature DB >> 22179013

Lysophosphatidic acid is a modulator of cyst growth in autosomal dominant polycystic kidney disease.

Bonnie L Blazer-Yost1, Brenda J Blacklock, Stephanie Flaig, Robert L Bacallao, Vincent H Gattone.   

Abstract

Autosomal dominant polycystic kidney disease (ADPKD) is characterized by the slow growth of multiple fluid-filled cysts predominately in the kidney tubules and liver bile ducts. Elucidation of mechanisms that control cyst growth will provide the basis for rational therapeutic intervention. We used electrophysiological methods to identify lysophosphatidic acid (LPA) as a component of cyst fluid and serum that stimulates secretory Cl- transport in the epithelial cell type that lines renal cysts. LPA effects are manifested through receptors located on the basolateral membrane of the epithelial cells resulting in stimulation of channel activity in the apical membrane. Concentrations of LPA measured in human ADPKD cyst fluid and in normal serum are sufficient to maximally stimulate ion transport. Thus, cyst fluid seepage and/or leakage of vascular LPA into the interstitial space are capable of stimulating epithelial cell secretion resulting in cyst enlargement. These observations are particularly relevant to the rapid decline in renal function in late-stage disease and to the "third hit" hypothesis that renal injury exacerbates cyst growth.
Copyright © 2011 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22179013      PMCID: PMC3709190          DOI: 10.1159/000335857

Source DB:  PubMed          Journal:  Cell Physiol Biochem        ISSN: 1015-8987


  42 in total

1.  Hormonal regulation of the epithelial Na+ channel: from amphibians to mammals.

Authors:  Michael Anne Shane; Charity Nofziger; Bonnie L Blazer-Yost
Journal:  Gen Comp Endocrinol       Date:  2006-01-06       Impact factor: 2.822

2.  Identification of a forskolin-like molecule in human renal cysts.

Authors:  William C Putnam; Sarah M Swenson; Gail A Reif; Darren P Wallace; George M Helmkamp; Jared J Grantham
Journal:  J Am Soc Nephrol       Date:  2007-01-24       Impact factor: 10.121

3.  Molecular basis of renal cyst formation--one hit or two?

Authors:  A C Ong; P C Harris
Journal:  Lancet       Date:  1997-04-12       Impact factor: 79.321

4.  Development of a phosphatase-resistant, L-tyrosine derived LPA1/LPA3 dual antagonist.

Authors:  James E East; Karen M Carter; Perry C Kennedy; Nancy A Schulte; Myron L Toews; Kevin R Lynch; Timothy L Macdonald
Journal:  Medchemcomm       Date:  2011-03-03       Impact factor: 3.597

5.  Polycystin 1 is required for the structural integrity of blood vessels.

Authors:  K Kim; I Drummond; O Ibraghimov-Beskrovnaya; K Klinger; M A Arnaout
Journal:  Proc Natl Acad Sci U S A       Date:  2000-02-15       Impact factor: 11.205

6.  LPA(4)/GPR23 is a lysophosphatidic acid (LPA) receptor utilizing G(s)-, G(q)/G(i)-mediated calcium signaling and G(12/13)-mediated Rho activation.

Authors:  Chang-Wook Lee; Richard Rivera; Adrienne E Dubin; Jerold Chun
Journal:  J Biol Chem       Date:  2006-12-13       Impact factor: 5.157

7.  Ki16425, a subtype-selective antagonist for EDG-family lysophosphatidic acid receptors.

Authors:  Hideo Ohta; Koichi Sato; Naoya Murata; Alatangaole Damirin; Enkhzol Malchinkhuu; Junko Kon; Takao Kimura; Masayuki Tobo; Yuji Yamazaki; Tomoko Watanabe; Mikio Yagi; Motoko Sato; Rika Suzuki; Hideko Murooka; Teruyuki Sakai; Tsuyoshi Nishitoba; Dong-Soon Im; Hiromi Nochi; Koichi Tamoto; Hideaki Tomura; Fumikazu Okajima
Journal:  Mol Pharmacol       Date:  2003-10       Impact factor: 4.436

8.  Anion secretion drives fluid secretion by monolayers of cultured human polycystic cells.

Authors:  R Mangoo-Karim; M Ye; D P Wallace; J J Grantham; L P Sullivan
Journal:  Am J Physiol       Date:  1995-09

Review 9.  Advances in the pathogenesis and treatment of polycystic kidney disease.

Authors:  Vishal Patel; Renuka Chowdhury; Peter Igarashi
Journal:  Curr Opin Nephrol Hypertens       Date:  2009-03       Impact factor: 2.894

Review 10.  Lipid mediators in health and disease: enzymes and receptors as therapeutic targets for the regulation of immunity and inflammation.

Authors:  Takao Shimizu
Journal:  Annu Rev Pharmacol Toxicol       Date:  2009       Impact factor: 13.820

View more
  5 in total

1.  Akt Regulates a Rab11-Effector Switch Required for Ciliogenesis.

Authors:  Vijay Walia; Adrian Cuenca; Melanie Vetter; Christine Insinna; Sumeth Perera; Quanlong Lu; Daniel A Ritt; Elizabeth Semler; Suzanne Specht; Jimmy Stauffer; Deborah K Morrison; Esben Lorentzen; Christopher J Westlake
Journal:  Dev Cell       Date:  2019-06-13       Impact factor: 12.270

2.  Tubular cell phenotype in HIV-associated nephropathy: role of phospholipid lysophosphatidic acid.

Authors:  Kamesh R Ayasolla; Partab Rai; Shai Rahimipour; Mohammad Hussain; Ashwani Malhotra; Pravin C Singhal
Journal:  Exp Mol Pathol       Date:  2015-06-14       Impact factor: 3.362

3.  Elevated level of lysophosphatidic acid among patients with HNF1B mutations and its role in RCAD syndrome: a multiomic study.

Authors:  Beata Małachowska; Justyna Janikiewicz; Karolina Pietrowska; Krystyna Wyka; Joanna Madzio; Kamila Wypyszczak; Marcin Tkaczyk; Sławomir Chrul; Rafał Zwiech; Anna Hogendorf; Maciej T Małecki; Maciej Borowiec; Adam Krętowski; Wojciech Młynarski; Agnieszka Dobrzyń; Michał Ciborowski; Wojciech Fendler
Journal:  Metabolomics       Date:  2022-02-18       Impact factor: 4.290

4.  Calcium-activated and apoptotic phospholipid scrambling induced by Ano6 can occur independently of Ano6 ion currents.

Authors:  A Kmit; R van Kruchten; J Ousingsawat; N J A Mattheij; B Senden-Gijsbers; J W M Heemskerk; R Schreiber; E M Bevers; K Kunzelmann
Journal:  Cell Death Dis       Date:  2013-04-25       Impact factor: 8.469

5.  Expression and role of GPR87 in urothelial carcinoma of the bladder.

Authors:  Homare Okazoe; Xia Zhang; Dage Liu; Shinsuke Shibuya; Nobufumi Ueda; Mikio Sugimoto; Yoshiyuki Kakehi
Journal:  Int J Mol Sci       Date:  2013-06-10       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.